Arcus Biosciences (RCUS) PT Lowered to $42 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RCUS Hot Sheet
Price: $19.31 +2.12%
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Arcus Biosciences (NYSE: RCUS) to $42.00 (from $48.00) while maintaining a Buy rating.
You May Also Be Interested In
- Arcus Biosciences (RCUS) Misses Q3 EPS by 12c
- First Industrial Realty Trust (FR) PT Lowered to $62 at Truist Securities
- Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
